Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Uncategorised

EY

Shorla Oncology co-founders win EY Entrepreneurs of the Year award

December 2nd 2024

Read More

Shorla Oncology

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

October 29th 2024

Read More

Logo

OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Banner

PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

October 4th 2023

Read More

Banner

Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection

May 16th 2023

Read More

Photo

CEO Sharon Cunningham met with Minister Robert Troy at Enterprise Ireland’s trade visit in Boston

March 7th 2022November 4th 2021

Read More

Shorla Oncology

Team Shorla Oncology complete 100k in 30 days for Breast Cancer

March 7th 2022June 30th 2021

Read More

Shorla Oncology

FDA filing acceptance and priority review received for SH-111

March 7th 2022April 23rd 2021

Read More

Photo

Shorla Oncology named Local Enterprise of the Year at The Irish Times Business Awards 2020

March 7th 2022September 3rd 2020

Read More

Older posts
Page1 Page2
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.